The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Open accessAbstract
BACKGROUND: More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection. METHODS: Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing events. RESULTS: With a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among nonusers of aspirin (difference, -4.3 percentage points; 95% confidence interval [CI], -5.0 to -3.6; adjusted hazard ratio, 0.69; 95% CI, 0.62 to 0.76). This inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hazard ratios were 0.90 (95% CI, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% CI, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% CI, 0.42 to 0.70) for 5 or more years of use. Ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazard ratio, 0.73 [95% CI, 0.67 to 0.81]). However, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and nonusers of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4). CONCLUSIONS: In a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Self-citationAustin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
The completeness of the Swedish Cancer Register – a sample survey for year 1998
Barlow, L., Westergren, K., Holmberg, L., & Talbäck, M. (2009) · Acta Oncologica · doi:10.1080/02841860802247664 · Cited by 1,236
Doubly robust estimation of causal effects
Funk, M. J., Westreich, D., Wiesen, C., Stürmer, T., Brookhart, M. A., & Davidian, M. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq439 · Cited by 1,158
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
Chan, T. A., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.681 · Cited by 579
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Austin, P. C. (2010) · Statistics in Medicine · doi:10.1002/sim.3854 · Cited by 356
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
Leng, J., Han, C., Demetris, J. A., Michalopoulos, G. K., & Wu, T. (2003) · Hepatology · doi:10.1053/jhep.2003.50380 · Cited by 258
Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men
Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Wu, K., & Fuchs, C. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.035 · Cited by 242
Self-citationNonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma
Sahasrabuddhe, V. V., Gunja, M. Z., Graubard, B. I., Trabert, B., Schwartz, L. M., Park, Y., Hollenbeck, A. R., Freedman, N. D., & McGlynn, K. A. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs452 · Cited by 222
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
Simon, T. G., Ma, Y., Ludvigsson, J. F., Chong, D. Q., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., Zhang, X., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4154 · Cited by 211
Self-citationMohanty, A., Tate, J. P., & Garcia-Tsao, G. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.007 · Cited by 206
Simon, T. G., Bonilla, H., Yan, P., Chung, R. T., & Butt, A. A. (2016) · Hepatology · doi:10.1002/hep.28506 · Cited by 180
Self-citationKern, M. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00094-0 · Cited by 170
Aspirin-triggered proresolving mediators stimulate resolution in cancer
Gilligan, M. M., Gartung, A., Sulciner, M. L., Norris, P. C., Sukhatme, V. P., Bielenberg, D. R., Huang, S., Kieran, M. W., Serhan, C. N., & Panigrahy, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804000116 · Cited by 166
Lee, T., Hsu, Y., Tseng, H.-C., Yu, S.-H., Lin, J., Wu, M., & Wu, C. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.8342 · Cited by 160
Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events
Sundström, J., Hedberg, J., Thuresson, M., Aarskog, P., Johannesen, K. M., & Oldgren, J. (2017) · Circulation · doi:10.1161/circulationaha.117.028321 · Cited by 137
Paik, Y. H., Kim, J. K., Lee, J. I., Kang, S. H., Kim, D. Y., An, S. H., Lee, S. J., Lee, D. K., Han, K.-H., Chon, C. Y., et al. (2009) · Gut · doi:10.1136/gut.2008.157420 · Cited by 131
Chen, H., Cai, W., Chu, E. S., Tang, J. T., Wong, C.-C., Wong, S. H., Sun, W., Liang, Q., Fang, J., Sun, Z., et al. (2017) · Oncogene · doi:10.1038/onc.2017.73 · Cited by 125
Lee, M., Chung, G. E., Lee, J., Oh, S., Nam, J. Y., Chang, Y. W., Cho, H., Ahn, H., Cho, Y. Y., Yoo, J., et al. (2017) · Hepatology · doi:10.1002/hep.29318 · Cited by 116
Petrick, J. L., Sahasrabuddhe, V. V., Chan, A. T., Alavanja, M. C. R., Freeman, L. E. B., Buring, J. E., Chen, J., Chong, D. Q., Freedman, N. D., Fuchs, C. S., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0126 · Cited by 95
Self-citationDuberg, A., Törner, A., Davíðsdóttir, L. G., Aleman, S., Blaxhult, A., Svensson, Å., Hultcrantz, R. W., Bäck, E., & Ekdahl, K. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.00982.x · Cited by 77
Self-citationAspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults
Hwang, I. C., Chang, J., Kim, K., & Park, S. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-23343-0 · Cited by 62
Low-dose aspirin use and cancer characteristics: a population-based cohort study
Jonsson, F., Yin, L., Lundholm, C., Smedby, K. E. E., Czene, K., & Yudi Pawitan, Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.411 · Cited by 59
Gao, J., Wen, S., Yang, W., Lu, Y., Tong, H., Huang, Z., Liu, Z., & Tang, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069309 · Cited by 58
Foderà, D., D’Alessandro, N., Cusimano, A., Poma, P., Notarbartolo, M., Lampiasi, N., Montalto, G., & Cervello, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1322.052 · Cited by 58
Törner, A., Stokkeland, K., Svensson, Å., Dickman, P. W., Hultcrantz, R. W., Montgomery, S., & Duberg, A. (2016) · Hepatology · doi:10.1002/hep.28775 · Cited by 50
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[40,41] Similarly, meta-analyses found statin use may be associated with reduced HCC risk, with a relative risk of 0.54, regardless of underlying disease.”
InfluentialImmunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Metadata
- Authors
- Simon, T. G., Duberg, A.-S., Aleman, S., Chung, R. T., Chan, A. T., & Ludvigsson, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-12
- Volume
- 382
- Issue
- 11
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011609327
- Cited by
- 304
- References
- 38
- FWCI
- 25.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.